Short description:
Personalized Synthetic Medicines
Drug notes:
IDE397 Clin2 NSCLC, esophagogastric cancer, Clin1 solid tumors (partner: Amgen); IDE161 Clin1 breast, ovarian cancers; 4 add'l products RD cancer
Long description:
IDEAYA Biosciences is using synthetic lethality to design therapeutics for cancer. Synthetic lethality is a situation where inhibition of two genes together - but not each individually - results in cell death. IDEAYA is exploiting synthetic lethality interactions to identify a novel set of drug targets across different organisms and in human tumor cells. To achieve this, IDEAYA is using their DECIPHER Dual CRISPR Synthetic Lethality library with proprietary data and collaborations with the Broad Institute of Harvard and MIT. IDEAYA has a diverse pipeline of drugs in clinical stage development for a variety of solid tumors.
Jobs:
Senior Clinical Trial Manager South San Francisco, CARemote|11 days ago
Director, Clinical Operations South San Francisco, CA San Diego, CaliforniaOn-site|14 days ago
Sr Principal Research Scientist / Associate Direct... South San Francisco, CAOn-site|17 days ago
Director, Business Development, Search and Evaluat... South San Francisco, CAOn-site|32 days ago
Vice President, Human Resources South San Francisco, CAOn-site|35 days ago
Director/Senior Director, Medical Writing South San Francisco, CA San Diego, CaliforniaHybrid|50 days ago
Director/Senior Director, DMPK and Clinical Pharma... South San Francisco, CA/ On-site|93 days ago
Payroll Manager South San Francisco, CA/ Hybrid|100+ days ago
Vice President, Corporate Strategy and Business De... San Francisco, CA|100+ days ago
Director / Sr Director, Medicinal Chemistry San Francisco, CA|100+ days ago